Clinical trials: Pathological Complete Response
Chronic Myeloid Leukemia
Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy
Rationale: At present, virtually no evidence exists regarding mid to long-term patient-reported health outcomes (e.g., health related quality of life-HRQOL) of CML patients treated with Imatinib.
- Trial name
- NCT00896129
- Testing
- HRQOL Survey Packet
- Where
- 25 sites in Italy
- Volunteers
- 448 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia
G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission
RATIONALE: Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant.
- Trial name
- NCT00233961
- Testing
- filgrastim
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
PMMR/MSS Adenocarcinoma of the Colon or Rectum, Neoadjuvant Chemoradiotherapy
Study on the Applicability of CCR Criteria in Rectal Cancer
This study aims to explore how well the usual ways of checking if rectal cancer patients are free of disease signs after treatment work for a new treatment method.
- Conditions
- PMMR/MSS Adenocarcinoma of the Colon or Rectum, Neoadjuvant Chemoradiotherapy, Immunotherapy, Complete Response
- Trial name
- NCT06794099
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Peking University Cancer Hospital & Institute
Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
This phase II trial studies how well pUMVC3-IGFBP2 plasmid deoxyribonucleic acid (DNA) vaccine (IGFBP-2 vaccine) and combination chemotherapy work in treating patients with stage III-IV ovarian, fallopian tube, or primary…
- Conditions
- Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer
- Trial name
- NCT03029611
- Testing
- Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Washington
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer
The goal of this clinical trial is to test a new combination treatment for locally advanced rectal cancer (cancer in the lower or middle part of the rectum that has not spread to distant organs).
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT07397442
- Testing
- Short-Course Radiotherapy Combined with Chemotherapy and Immunotherapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Beijing Friendship Hospital
Breast Cancer
Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy
Patients with stage II-III breast cancer who do not achieve a pathologic complete response to neoadjuvant chemotherapy at the time of surgery will be treated with oral low dose continuous cyclophosphamide and methotrexate (CM) in…
- Trial name
- NCT01612247
- Testing
- Cyclophosphamide and Methotrexate and Aspirin
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Vermont
Breast Cancer
Prospective Validation of Ataraxis AI Test for Predicting Treatment Response in Neoadjuvant Breast Cancer
This study evaluates the real-world clinical workflow integration of a previously developed artificial intelligence (AI) prognostic test in breast cancer patients receiving neoadjuvant chemotherapy, and validates its accuracy in…
- Trial name
- ATARAXIS NEOP (NCT07327970)
- Testing
- multi-modal foundation AI test
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Young-Joon Kang
Breast Cancer
This Study Investigates the Impact of Single Nucleotide Polymorphisms in Genes Involved in the Pharmacokinetics and Toxicity of Doxorubicin (DOX) in Egyptian Female Patients with Breast Cancer. It Also Aims to Explore the Association of Pretreatment Neutrophil to Lymphocyte Ratio to PCR
This study aims to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in doxorubicin transport and metabolism on its pharmacokinetics and toxicity in Egyptian breast cancer patients.
- Trial name
- NCT06595758
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Menoufia University
Breast Neoplasm Female
Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer
This study evaluates whether sequential neo-adjuvant chemotherapy plus surgery followed by Capecitabine could achieve additional benefits over traditional postoperative chemotherapy.
- Trial name
- NACVCAC (NCT03011060)
- Testing
- Neo-adjuvant Chemotherapy, Capecitabine
- Where
- China
- Volunteers
- 1,588 people
- Sponsor
- The First Hospital of Jilin University
Rectal Cancer Patients
Impact Of Metformin In Rectal Cancer Patients
Design: Prospective, randomized controlled clinical trial Setting: at Minia University Hospital and Minia Oncology Institute. Condition: Colorectal cancer.
- Trial name
- NCT06728982
- Testing
- Metformin
- Where
- 2 sites in Egypt
- Volunteers
- 85 people
- Sponsor
- Minia University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Trial name
- NCT06876714
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Echocardiography
- Where
- 702 sites in United States, Puerto Rico
- Volunteers
- 1,524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Motor Complete Spinal Cord Injury
The Effects of Passive Gait Training in Complete Motor Spinal Cord Injury (SCI)
The purpose of this study is to determine whether a three times per week, 2 month robotic assisted treadmill gait training program, will beneficially affect the fitness, physical and psychological well-being, and the vascular and…
- Trial name
- NCT01349478
- Testing
- LOKOMAT
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- Dr. Gabriel Zeilig
Chronic Myeloid Leukemia
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha
To investigate whether patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib)…
- Trial name
- NCT01073436
- Testing
- Discontinuation of therapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chronic Myeloid Leukemia, Imatinib
Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib
This prospective study is performed to identify safer and more concrete indicators of successful discontinuation and explore contributing factors for sustained undetectable transcript
- Conditions
- Chronic Myeloid Leukemia, Imatinib, Complete Molecular Response
- Trial name
- NCT01564836
- Testing
- Imatinib treatment discontinuing
- Where
- 2 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul St. Mary's Hospital
Acute Myeloid Leukemia
CNDO-109-AANK for AML in First Complete Remission (CR1)
This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a…
- Trial name
- NCT01520558
- Testing
- CNDO-109-AANK Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Coronado Biosciences, Inc.
Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if cadonilimab combined with anlotinib can be a safe and effective neoadjuvant therapy in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06426797
- Testing
- Cadonilimab plus anlotinib
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
Some patients with antibody-mediated autoimmune hematological diseases (warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (cAIHA) and immune thrombocytopenia (ITP)) shows no or only minor and transient response to…
- Trial name
- Ixa-Cyto (NCT03965624)
- Testing
- Ninlaro
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Locally Advanced Rectal Carcinoma
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
The aim of this clinical trial is to compare triplet induction therapy (FOLFOXIRI) with doublet induction therapy (CAPOX/FOLFOX), followed by chemoradiotherapy and either surgery or a watch-and-wait approach, in patients with…
- Trial name
- MEND-IT II (NCT07472868)
- Testing
- FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 20 sites in Netherlands
- Volunteers
- 394 people
- Sponsor
- J. W. A. Burger
Breast Cancer, Triple Negative Breast Neoplasms
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Primary aim: To compare the effect on pathologic complete response (pCR) rate of adding capecitabine to carboplatin based preoperative chemotherapy in early ER-negative and HER2-negative breast cancer.
- Trial name
- NCT04335669
- Testing
- epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab, epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab
- Where
- 24 sites in Denmark, Sweden
- Volunteers
- 325 people
- Sponsor
- Lund University Hospital
Preterm Infant, Early-Onset Neonatal Sepsis
Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants
This study evaluates the utility of placental/umbilical cord blood (PUCB) to perform the baseline workup testing for EONS in Very Low Birth Weight Infants: CBC (Complete Blood Count) with differential, Immature/Total ratio (I/T…
- Conditions
- Preterm Infant, Early-Onset Neonatal Sepsis, Umbilical Cord
- Trial name
- NCT03694613
- Testing
- Placental/Umbilical Cord Blood sample
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- The University of Texas Medical Branch, Galveston